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Over a decade ago Polymerase δ interacting protein of 38 kDa (PDIP38) was proposed to
play a role in DNA repair. Since this time, both the physiological function and subcellular
location of PDIP38 has remained ambiguous and our present understanding of PDIP38
function has been hampered by a lack of detailed biochemical and structural studies. Here we
show, that human PDIP38 is directed to the mitochondrion in a membrane potential
dependent manner, where it resides in the matrix compartment, together with its partner
protein CLPX. Our structural analysis revealed that PDIP38 is composed of two conserved
domains separated by an α/β linker region. The N-terminal (YccV-like) domain of PDIP38
forms an SH3-like β-barrel, which interacts specifically with CLPX, via the adaptor docking
loop within the N-terminal Zinc binding domain of CLPX. In contrast, the C-terminal
(DUF525) domain forms an immunoglobin-like β-sandwich fold, which contains a highly
conserved putative substrate binding pocket. Importantly, PDIP38 modulates the substrate
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function of mitochondrial PDIP38, demonstrating that PDIP38 is a bona fide adaptor protein
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itochondria are essential organelles that play crucial
roles in energy transduction, haem biosynthesis, fatty
acid oxidation and cell signalling. Although the vast
majority of mitochondrial proteins (~99%) are encoded on
nuclear DNA, human mitochondria also contain a small genome
(mtDNA) that encodes 13 polypeptides. This distribution
of mitochondrial genes (over two genomes) creates a number of
challenges for mitochondria, most notably the maintenance of
protein homeostasis (proteostasis) within the organelle. Con-
sistent with the importance of proteostasis within this organelle,
genetic mutations in components of the mitochondrial proteos-
tasis network (PN) have been linked to mitochondrial dysfunc-
tion, disease and aging1,2.
A key aspect of mitochondrial proteostasis is the regulated
removal of damaged or unwanted proteins. In humans, this
process is performed by five different AAA+ (ATPases associated
with a variety of cellular activities) proteases, three of which are
located in the inner membrane (two forms of the m-AAA
(matrix-AAA) protease and a single i-AAA (intermembrane
space-AAA) protease3) and two of which are located in the
matrix, LONM (encoded by a single gene, LONP1) and CLPXP
(encoded by two genes, CLPX and CLPP). Although deletion of
LONP1 is embryonically lethal4 and LONM is regarded as the
principal AAA+ protease of the matrix compartment5–8, genetic
mutations in CLPX and CLPP are associated with severe phe-
notypes in mice and diseases in humans9–11. Consistently,
mammalian CLPXP is reported to play a critical role in a variety
of important functions, including mitoribosome assembly12 and
haem regulation11,13,14. Likewise, compounds that dysregulated
mitochondrial CLPP15 exhibit therapeutic potential against spe-
cific cancer cells16–18. Despite the emerging importance of this
protease in human health and disease, only a handful of CLPXP
substrates have been verified. Furthermore, given human CLPX
exhibits a distinct substrate specificity relative to its bacterial
homologues15,19, our current understanding of this proteolytic
machine is limited.
Like most AAA+ proteases20–23, human CLPXP is composed
of two components: a peptidase component, CLPP and a AAA+
unfoldase component, CLPX24–26. The peptidase component
forms a barrel-shaped oligomer that is composed of two hepta-
meric rings, stacked back-to-back. To prevent the indiscriminate
turnover of proteins, the catalytic residues of CLPP are encap-
sulated within the barrel and access to the proteolytic chamber is
limited to a narrow entry portal at either end of the cylinder.
The unfoldase component CLPX, forms a hexameric ring that sits
at one or both ends of CLPP acting as a gatekeeper to the pro-
teolytic chamber. As such, CLPX is not only responsible for
recognition of the substrate, but also for its ATP-dependent
unfolding and translocation into the proteolytic chamber of
CLPP27. In the case of Escherichia coli ClpX (ecClpX), substrate
recognition is mediated by various distinct loops and regions
(i.e. pore loops and accessory domains), some of which are
exclusively required for particular substrates19,28,29. In addition to
the direct recognition of substrates, some AAA+ proteases also
use specialised cofactors (commonly referred to as adaptor pro-
teins) to alter substrate recognition and/or specificity30–34. Cur-
rently, however, no AAA+ adaptor proteins have been identified
in mammalian mitochondria.
Previously, we identified mouse polymerase δ-interacting
protein of 38 kDa (PDIP38, also known as POLDIP2) as a
putative mitochondrial CLPX-interacting protein15. However,
since its discovery in a yeast two-hybrid screen, as a p50 and
PCNA-interacting protein35, the subcellular distribution of
PDIP38 and its physiological function have remained perplexing.
Indeed, over the past 20 years, there have been several conflicting
reports examining the subcellular location of tagged or
endogenous PDIP38. To date, PDIP38 has been identified in the
nucleus36,37, the mitochondrion15,38, the cytoplasm39–41 and the
plasma membrane39,40, where it is proposed to mediate a variety
of cellular functions, including cell proliferation40, regulation of
the extracellular matrix42, oxidative signalling and cell migra-
tion43, Tau aggregation44, cancer45 and DNA repair37,39,41,46.
However, several of these cellular studies have incorporated
EGFP-tagged versions of PDIP38 (which when attached to the N
terminus of PDIP38 prevent its targeting to the mitochondrion)
and very few of the putative interactions have been validated
in vitro. As such, the physiological significance of some of these
proposed functions remain uncertain. Nevertheless, consistent
with our previous identification of PDIP38 as a CLPX-interacting
protein, Martin and colleagues47 recently proposed that PDIP38
controls the lipoylation of pyruvate dehydrogenase and α-
ketoglutarate dehydrogenase complexes by inhibiting CLPXP.
However, the details of its interaction with CLPX and how it
regulates CLPXP activity are currently unknown.
Here we show that human PDIP38 is targeted to the mito-
chondrion via an N-terminal presequence and imported into the
matrix compartment in a Δψ-dependent manner, where it colo-
calises with its partner proteins CLPX and CLPP. Critically,
PDIP38 is neither degraded by CLPXP nor does it trigger dis-
sociation of the CLPXP complex. Rather, PDIP38 modulates the
specificity of CLPXP in vitro and alters the stability of CLPX both
in vitro and in cells. Hence, we propose that mitochondrial
PDIP38 is a specialised adaptor protein for the CLPXP protease.
Consistent with this role, PDIP38 is composed of two domains,
an N-terminal “YccV-like” domain, which docks to a specific
adaptor binding loop within the zinc-binding domain (ZBD) of
CLPX, and a C-terminal domain of unknown function (DUF525),
which forms an immunoglobulin-like fold. Interestingly, although
the binding repertoire of PDIP38 is currently unknown, based on
our PDIP38 structure and its similarity to Fbxo3 (the substrate
recognition component of a Skp Cullin F-box (SCF) E3 ligase), we
propose that PDIP38 recognises a ligand via a conserved pocket.
Importantly, mutation of the adaptor-docking loop in human
CLPX specifically inhibited PDIP38 docking, without effecting
peptide (substrate) binding. Taken together, we propose that
mitochondrial PDIP38 represents the first adaptor protein for the
AAA+ protease, CLPXP.
Results
Human PDIP38 is targeted to the mitochondrial matrix, where
it associates with CLPX. Although PDIP38 was originally
described as a nuclear protein, it has been reported to localise to
several subcellular compartments, including the mitochondrion,
the cytosol and even the plasma membrane. As a result of the
broad and uncertain subcellular distribution of PDIP38, its
physiological function currently remains unclear. Therefore, in
order to resolve this ambiguity, we examined the in vitro import
of radiolabelled human preprotein (pre-PDIP38) into isolated
mitochondria and performed mitochondrial fractionation
experiments (Fig. 1). Consistent with previous studies from ours
and other groups15,38,47, these in vitro import data clearly
demonstrate that the PDIP38 preprotein (pre-PDIP38) is
imported into isolated mitochondria in a membrane potential-
dependent manner (Fig. 1a, compare lanes 11 and 12). Impor-
tantly, the processed, mature (mt) form of the protein (mt-
PDIP38) was protected from cleavage by proteinase K (Prot. K),
demonstrating that mt-PDIP38 (herein referred to as PDIP38)
was sequestered inside mitochondria. As expected for a matrix
localised protein, PDIP38 was protected from digestion by Prot. K
in both intact mitochondria (Fig. 1b, lanes 1–4) and mitoplast
(Fig. 1b, lanes 5–8), similar to the known matrix protein CLPP
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(Fig. 1b, bottom panel). As a control, the outer membrane protein
(TOM20) was digested by Prot. K under all conditions, while
the inner membrane protein (TIM23) was completely protected
in intact mitochondria, but sensitive in mitoplast (Fig. 1b,
lanes 5–8). Next, having confirmed that human PDIP38 is a
mitochondrial matrix protein, we examined the interaction
between CLPX and PDIP38 in human mitochondria by co-
immunoprecipitation (co-IP). Initially, we monitored the inter-
action of endogenous CLPX (with endogenous PDIP38), using a
PDIP38-specific antisera. Consistent with a specific interaction
between PDIP38 and CLPX, CLPX was only recovered in the
presence of protein A sepharose (PAS)-immobilised anti-PDIP38
antibodies (Fig. 1c, lane 3, lower panel) and not in the presence of
PAS-immobilised preimmune antibodies (Fig. 1c, lane 2, lower
panel). Next, to confirm this interaction, we performed the
reverse co-IP, in which antibodies from anti-CLPX antisera were
immobilised to PAS. Consistent with the specific IP of CLPX with
anti-PDIP38 antibodies, the IP of CLPX using anti-CLPX anti-
bodies also resulted in the specific co-IP of PDIP38 (Fig. 1d, lane
3, lower panel). Next, to confirm the interaction, we immobilised
a His10-tagged version of recombinant PDIP38 (H10PDIP38) to
Ni-NTA agarose and performed a pull-down using detergent-
solubilised HeLa mitochondria. Consistent with the co-IPs above,
CLPX was only recovered from the column containing immobi-
lised PDIP38 (Supplementary Fig. 1, lane 6) and not from the
control columns (Supplementary Fig. 1, lanes 5 and 7). Next, to
ensure the interaction that we observed in cells (between PDIP38
and CLPX) was direct, we purified both components and exam-
ined the interaction in vitro. Specifically, we generated recombi-
nant GST-PDIP38 fusion protein in which PDIP38 was fused to
the C terminus of GST. Following expression of GST-PDIP38, a
soluble lysate (bearing overexpressed GST-PDIP38) was applied
to Ni-NTA agarose beads (either lacking or containing immobi-
lised His10-tagged CLPX). Following incubation of GST-PDIP38
with the beads and subsequent wash steps, H10CLPX together
with the bound proteins was eluted from the column with imi-
dazole (Fig. 2a, lanes 4 and 7). Consistent with our identification
of PDIP38 as a CLPX-interacting protein (Fig. 1), GST-PDIP38
was only recovered in the presence of immobilised H10CLPX
(Fig. 2a, lanes 7) and not in the absence of an immobilised protein
(Fig. 2a, lanes 4).
PDIP38 is neither a substrate of CLPXP nor does it trigger
dissociation of the CLPXP complex. Next, we examined the
consequence of PDIP38 docking to CLPX, to determine if
PDIP38 is a substrate of the CLPXP protease or a regulator that
triggers dissociation of the CLPXP complex? To determine if
PDIP38 is a substrate of CLPXP, we monitored the stability of
purified recombinant mature PDIP38 in vitro, in the presence of
active CLPXP (Fig. 2b). Given that substrate recognition by many
Clp proteases is generally mediated by degrons located at either
the N or C termini48, we generated an untagged version of
PDIP38, using the Ub-fusion system49. As a control, to ensure
that human CLPXP was active, we monitored the turnover of
casein, a model unfolded protein and well-characterised CLPXP
substrate15,26. Significantly, in contrast to the rapid CLPXP-
mediated turnover of fluorescein isothiocyanate (FITC)-labelled
casein (FITC-casein) (Fig. 2b, middle panel), the levels of
untagged PDIP38 remained unchanged throughout the time
course of the experiment (Fig. 2b, upper panel). These data clearly
demonstrate that mature PDIP38 is not a substrate of the CLPXP
protease; however, it remained unclear if the lack of PDIP38
turnover was due to dissociation of the CLPXP complex (trig-
gered by PDIP38 docking to CLPX). To examine this possibility,
we monitored the CLPXP-mediated turnover of FITC-casein in
the presence of PDIP38 (Fig. 2b, lower panel). Interestingly, the
addition of PDIP38 produced distinct effects on the turnover of
FITC-casein. Although the turnover of αS2-casein was inhibited
by PDIP38 (Fig. 2b, lower panel), in a concentration-dependent
manner (Supplementary Fig. 2), the turnover of αS1- and κ-casein
was unaffected by the presence of PDIP38 (Fig. 2b, lower panel
and Supplementary Fig. 2, black bars). Given that the CLPXP-
mediated turnover of κ-casein was unchanged by PDIP38 addi-
tion, these data suggest that the CLPXP complex remains intact in
the presence of PDIP38. To confirm that PDIP38 interacts not
only with CLPX, but also with CLPXP, we examined complex
formation using fluorescence detected analytical ultracentrifuga-
tion (FD-AUC). Specifically, we generated a GFP-PDIP38 fusion
protein and examined its sedimentation (in the absence or pre-
sence of CLPX with or without the addition of CLPP). The use of
GFP-PDIP38 allowed specific detection (by GFP fluorescence) of
Fig. 1 Human PDIP38 is imported into mitochondria where it interacts
with CLPX. a Import of [35S]-labelled PDIP38 preprotein into mitochondria
isolated from HeLa cells, in the presence or absence of a membrane
potential (∆ψ) as indicated, treated with (lanes 7–12) or without (lanes
1–6) proteinase K (Prot. K). Samples were separated by 15% Tris-glycine
SDS-PAGE and analysed by digital autoradiography. Full gel is shown in
Supplementary Fig. 13. b Mitochondria were incubated, either in an osmotic
buffer (lanes 1–4), isotonic buffer (Swelling) to rupture the outer membrane
(lanes 5–8) or buffer containing Triton X-100 (lanes 9–12), in the absence
(lanes 1, 5 and 9) or presence (lanes 2–4, 6–8 and 10–12) of Prot. K for the
indicated time. Samples were separated by 16.5% Tricine-buffered SDS-
PAGE and subjected to immunoblotting with the appropriate antisera to
visualise endogenous proteins. *Non-specific cross-reactive protein
recognised by PDIP38 antisera. Full immunoblots are shown in
Supplementary Fig. 14. c Specific immunoprecipitation (IP) of endogenous
PDIP38 from detergent-solubilised mitochondria using anti-PDIP38
polyclonal antibodies showing co-immunoprecipitation of endogenous
CLPX. The input represents 50% of total mitochondrial lysate subjected to
IP. Pre preimmune serum. Full immunoblot strips are shown in
Supplementary Fig. 13. d Specific immunoprecipitation of endogenous CLPX
from detergent-solubilised mitochondria using anti-CLPX polyclonal
antibodies showing co-immunoprecipitation of endogenous PDIP38. The
input represents 50% of total mitochondrial lysate subjected to IP. Full
immunoblot strips are shown in Supplementary Fig. 13.
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complexes that only contained PDIP38 and eliminated the
detection of subcomplexes of CLPX and/or CLPXP that lacked
PDIP38. To monitor the interaction of PDIP38 with CLPX and
CLPXP complexes, all FD-AUC experiments were performed
using the CLPXTRAP mutant15 in the presence of 5 mM ATP.
Initially, we examined the sedimentation of GFP-PDIP38 (Fig. 2c,
open circles). As expected for a protein of ~65 kDa, GFP-PDIP38
sedimented in a single peak with an s20,w of ~5.8 S. Next, we
examined the sedimentation of GFP-PDIP38 in the presence of
CLPX. Consistent with the previously observed sedimentation of
hexameric CLPX s20,w ~14 S50, GFP-PDIP38 (in the presence of
CLPX) sedimented with an s20,w of ~16.5 S (Fig. 2c, red triangles),
indicating the GFP-PDIP38 interacts with hexameric CLPX.
Finally, we examined the sedimentation of GFP-PDIP38 in the
presence of both CLPX and CLPP. As expected, the sedimenta-
tion of GFP-PDIP38 shifted (from ~5.8 S) to a main peak of
s20,w ~22 and a shoulder at s20,w ~28 (Fig. 2d, blue circles).
These data are consistent with previous AUC analysis of CLPXP
complexes50, and the two peaks likely represent GFP-PDIP38
bound to single- and double-headed complexes of CLPXP.
Nevertheless, to ensure that both peaks represented specific
CLPXP complexes and were not due to a non-specific interaction
of GFP-PDIP38 with CLPP, we also examined the sedimentation
of GFP-PDIP38 in the presence of CLPP (Fig. 2d, black circles).
Consistent with a specific interaction of PDIP38 with CLPX,
the sedimentation of GFP-PDIP38 was unchanged in the pre-
sence of CLPP alone. Taken together, these data demonstrate
that PDIP38 is neither a substrate of the CLPXP machine nor
does it trigger dissociation of CLPX from CLPXP. Rather,
PDIP38 specifically inhibits the turnover of one form of casein
without affecting the turnover of another, and hence, similar to
known AAA+ adaptor proteins30,51–55, modulates the substrate
selectivity of CLPX.
PDIP38 docks to the “adaptor binding” loop within the ZBD
of CLPX. Next, we asked the question how does the CLPX-
PDIP38 complex form? Based on the findings above, we specu-
lated that PDIP38 could be an adaptor protein of human CLPX,
and as such would likely bind to an accessory domain of CLPX, as
is the case for several bacterial AAA+ adaptor proteins28–30,52.
Interestingly, in contrast to bacterial ClpX homologues, human
CLPX contains two accessory domains, an N-terminal C4-type
zinc-finger domain (commonly referred to as a ZBD) and an
additional domain that is inserted into the AAA module of CLPX,
which is unique to eukaryotic CLPX homologues (termed the E-
domain56). Therefore, to identify which CLPX domain (or
domains) might be responsible for the interaction with PDIP38,
we purified H10-tagged versions of both the ZBD and the E-
domain (Fig. 3a) of CLPX. These proteins were then immobilised
to Ni-NTA agarose and a soluble lysate bearing GST-PDIP38 was
applied to the appropriate columns (Fig. 3b, lane 2, 5 and 8).
Consistent with the data above, in which PDIP38 was recovered
in the presence of full-length CLPX, PDIP38 was specifically co-
eluted from the column containing immobilised ZBD (Fig. 3b,
lane 10) and not from the column containing immobilised E-
domain (Fig. 3b, lane 7). Collectively, these data demonstrate that
PDIP38 interacts specifically with the ZBD of CLPX. Next, we
performed a series of pull-down experiments to examine the
affinity of this interaction (Supplementary Fig. 3). From these
data, we estimate that PDIP38 binds to the ZBD of human CLPX
with a binding affinity (Kd ~1.8 µM) that is similar to other AAA
+ adaptor proteins57–59. We then examined the stoichiometry of
the interaction between PDIP38 and the ZBD. To do so, we
purified full-length PDIP38 (containing an N-terminal H10-tag)
and monitored complex formation by size-exclusion chromato-
graphy, using Superose 12. Consistent with its theoretical MW
(38.3 kDa), PDIP38 eluted in a single peak (Fig. 3c, upper panel)
Fig. 2 PDIP38 forms a complex with CLPX (and CLPXP), but is not a CLPXP substrate. a Coomassie Brilliant Blue (CBB) stained 16.5% Tricine-buffered
SDS-PAGE of PDIP38 pull-down from E. coli lysate containing recombinant GST-PDIP38, using beads either lacking (control) or containing immobilised
H10CLPX (CLPX). T total E. coli lysate with expressed GST-PDIP38, U unbound fraction, E eluted fraction. Lane 1, SeeBlue Plus MW protein standards. b In
vitro degradation assay of PDIP38 (upper panel) or FITC-labelled casein by CLPXP protease in the absence or presence of 2.4 µM untagged PDIP38 (lower
panels, as indicated). Samples were separated by 16.5% Tricine-buffered SDS-PAGE and analysed by fluorescence detection (FITC-casein) or CBB staining
(PDIP38). Full gels are shown in Supplementary Fig. 15. c, d c(s) distribution profiles for GFP-PDIP38 in the presence of 5 mM ATP (open circles) with the
addition of either CLPXTRAP (red triangles), CLPXTRAPP (blue circles) or CLPP (black circles).
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with an estimated molecular weight of ~45 kDa. In contrast, the
ZBD of CLPX (Fig. 3c, middle panel) eluted at ~15 ml, (estimated
MW of ~29 kDa), which is approximately double its theoretical
MW (12.1 kDa) and hence similar to the other ClpX homologues,
likely forms a homodimer (ZBD2). Consistent with the pull-down
(Fig. 3b and Supplementary Fig. 3), PDIP38 formed a stable
complex with CLPXZBD, which is based on the elution volume of
the complex (~13.6 ml, equivalent to ~60 kDa) is likely a het-
erodimeric complex composed of PDIP38 bound to ZBD2 (the-
oretical MW= 62.5 kDa) (Fig. 3c, lower panel). Next, to gain a
better understanding of the specificity of this interaction (between
PDIP38 and CLPX), we compared the ZBD of several ClpX
homologues, from both pro- and eukaryotic species (Fig. 3d),
focusing on a particular region within the domain that is
important for adaptor docking28,60,61. Interestingly, despite broad
conservation of the entire domain, there was considerable
sequence divergence across the putative adaptor-docking region
(Fig. 3d). Therefore, we hypothesised that this region may have
co-evolved with a new adaptor protein (i.e. PDIP38). To test this
idea, we compared the ability of the human CLPX ZBD and
ecClpX ZBD (ecZBD) to interact with human PDIP38 (Fig. 3e).
As predicted, human PDIP38 was exclusively recognised by
human ZBD (Fig. 3e, lane 1) as GST-PDIP38 was not recovered
in the presence of ecZBD (Fig. 3e, lane 3). Next, to determine
which part of the adaptor-docking region was required for
interaction with PDIP38, we generated a specific mutation within
this region, in which residues 120–123 (SSTR) of human CLPX
were replaced with AAAA in either full-length CLPX (here
referred to as CLPX4A) or the ZBD of CLPX (here referred to as
ZBD4A). Consistent with the lack of binding of PDIP38 to ecZBD,
Fig. 3 PDIP38 interacts with the adaptor-docking loop of human CLPXZBD. a Schematic representation of human CLPX domain structure. mts
mitochondrial targeting sequence, ZBD zinc-binding domain, E eukaryotic domain, AAA ATPase associated with a variety of cellular activities domain.
b Coomassie-stained 16.5% Tricine-buffered SDS-PAGE of PDIP38 pull-down from E. coli lysate expressing recombinant GST-PDIP38 using bead
immobilised H10CLPX E-domain (CLPXE) and H10CLPX zinc-binding domain (ZBD) relative to beads only (control). T total lysate expressing GST-PDIP38,
U unbound fraction, E eluted fraction. For comparison purified recombinant CLPXE (lane 11), ZBD (lane 12) and GST-PDIP38 (lane 13) are shown. c Complex
formation of PDIP38 and ZBD was monitored by size-exclusion chromatography (SEC) using a Superose 12 column. Elution profiles of PDIP38 (upper
panel), ZBD (middle panel) or PDIP38 in the presence of ZBD (bottom panel) were determined from quantification of protein bands (inset). Arrows
indicate the peak elution volume of albumin (67 kDa), ovalbumin (43 kDa), chymotrypsin A (25 kDa) and ribonuclease (13.7 kDa). d Amino acid sequence
alignment of eukaryotic and prokaryotic CLPX homologues showing part of the ZBD. The prokaryotic ClpX adaptor-docking loop is highlighted in the boxed
section. ClpX sequences are Homo sapiens (O76031); Mus musculus (Q9JHS4); Bos taurus (F1N155); Drosophila melanogaster (Q9VDS7), Escherichia coli
(P0A6H1), Caulobacter crescentus (P0CAU2), Bacillus subtilis (P50866) and Mycobacterium tuberculosis (P9WPB9). e In vitro pull-down, in which purified
human (lanes 1 and 2) or E. coli (lanes 3 and 4) ZBD was immobilised to Ni-NTA agarose beads and incubated with (lanes 1 and 3) or without (lanes 2 and
4) an E. coli lysate containing expressed recombinant GST-PDIP38. Eluted fractions are shown with samples analysed by CBB staining. f In vitro pull-down,
in which purified wild-type (WT, lanes 1 and 2) or mutant (4A, lanes 3 and 4) ZBD and wild-type (WT, lanes 5 and 6) or mutant (4A, lanes 7 and 8) human
H10CLPX was immobilised to Ni-NTA agarose beads and incubated with (lanes 1, 3, 5 and 7) or without (lanes 2, 4, 6 and 8) an E. coli lysate expressing
untagged PDIP38. Eluted proteins were separated by SDS-PAGE and visualised by CBB staining. g Binding of wild type (ZBD) and mutant (ZBD4A) to
overlapping 13-mer peptides representing mature mtSSB. Peptide sequences for numbered spots are shown in Supplementary Fig. 4. Highlighted spots
illustrate that the ZBD of human CLPX favours binding to peptides with a hydrophobic core and a net negative charge.
COMMUNICATIONS BIOLOGY | https://doi.org/10.1038/s42003-020-01358-6 ARTICLE
COMMUNICATIONS BIOLOGY |           (2020) 3:646 | https://doi.org/10.1038/s42003-020-01358-6 | www.nature.com/commsbio 5
the recovery of untagged PDIP38 to either immobilised ZBD4A
(Fig. 3f, lane 3) or CLPX4A (Fig. 3f, lane 7) was completely
abolished, when compared to wild-type ZBD (Fig. 3f, lane 1) or
CLPX (Fig. 3f, lane 5). Collectively, these data suggest that this
region, which we refer to as the “adaptor-docking loop” of CLPX,
performs a conserved function in bacterial and eukaryotic
homologues of CLPX. Specifically, the ZBD of human CLPX
forms a crucial docking platform for interaction with the putative
adaptor protein PDIP38. To ensure that this change to PDIP38
docking was not due to overall dysfunction of the ZBD or to a
dramatic change in its substrate specificity, we examined the
peptide binding specificity of wild-type and mutant ZBD using a
cellulose-bound (13-mer) peptide library (Fig. 3g, Supplementary
Fig. 4 and Supplementary Fig. 5). Similar to most chaperones and
proteases, the ZBD favoured recognition of peptides bearing a
short (2–4 residues long) hydrophobic core (Fig. 3g and Sup-
plementary Fig. 4); however, in contrast to most chaperones62,
the ZBD favoured peptides with an overall negative charge
(Fig. 3g, compare spots 30 and 31). Importantly, the peptide
binding specificity of both wild-type ZBD (Fig. 3g, upper panel)
and ZBD4A (Fig. 3g, lower panel) was essentially identical,
demonstrating that mutation of the adaptor-docking loop speci-
fically inhibited PDIP38 docking without affecting peptide
binding. Collectively, these data suggest that PDIP38 docks to
CLPX, likely as an adaptor protein for the CLPXP protease.
PDIP38 inhibits the LONM-mediated turnover of CLPX
in vitro and stabilises the steady-state levels of CLPX in cells.
Next, we asked the question what is the consequence of the
interaction (between PDIP38 and CLPXP) in cells? To address
this question, we knocked down PDIP38 expression in human
(HeLa) cells using small interfering RNA (siRNA). Following
successful knock down of PDIP38 (Fig. 4a, middle panel, compare
lanes 1–3 with lanes 4–6), using the PDIP38-specific siRNA
(#22994, Thermo Fisher Scientific), we analysed the steady-state
levels of selected mitochondrial proteins. From this analysis, we
identified that the levels of CLPX were reduced in HeLa cells
transfected with the PDIP38-specific siRNA (Fig. 4a, upper panel,
lanes 1–3) when compared to the levels of CLPX in HeLa cells
transfected with a control siRNA (Fig. 4a, lanes 4–6). Impor-
tantly, this change was specific to CLPX as the levels of CLPP
(Fig. 4a, lower panel) and the cross-reactive band recognised by
the anti-PDIP38 antisera (Fig. 4a, middle panel, *) were
unchanged by PDIP38 knockdown. These data suggest that
PDIP38 plays an important role in maintaining the steady-state
levels of CLPX in the cell. To validate this finding, we compared
the steady-state levels of CLPX in cells treated with an alternative
PDIP38-specific siRNA (either s25055 or s25056) with an addi-
tional control siRNA (Supplementary Fig. 6). Significantly, the
loss of CLPX (as a result of PDIP38 knockdown) was specific, as
the steady-state levels of two unrelated proteins (i.e. mitochon-
drial SDHA and the cytosolic protein, GAPDH) were not affected
(Supplementary Fig. 6b, lower panels). Interestingly, these data
are reminiscent of an unrelated bacterial adaptor protein—ClpS,
which protects its cognate unfoldase (ClpA) from autocatalytic
degradation in vivo52. Therefore, in order to determine if the
levels of CLPX were regulated by its autocatalytic turnover, we
examined the stability of CLPX in vitro, in the presence of CLPP
with or without the addition of PDIP38 (Supplementary Fig. 7a).
Fig. 4 PDIP38 stabilises CLPX protecting it from LONM-mediated degradation. a Representative immunoblots showing the steady-state levels of CLPX
(upper gel strip), PDIP38 (middle gel strip) and CLPP (lower gel strip) in PDIP38-depleted HeLa cells (lanes 1–3) relative to control HeLa cells (lanes 4–6).
Samples were collected at the indicated times post transfection of either Silencer Select siRNA (22994) targeting PDIP38 or a negative control siRNA
(control). Proteins were separated by 15% Tris-glycine SDS-PAGE. *Non-specific cross-reactive protein in PDIP38 antisera. Full immunoblots are shown in
Supplementary Fig. 16. The lower panel shows the quantitation of CLPX levels from three independent experiments, in PDIP38-depleted HeLa cells (grey
bars, each blue cross represents an individual experiment) in comparison a negative control siRNA (white bars, each red plus represents an individual
experiment). Initial level of CLPX was set to 100% 24 h post transfection in control. Error bars represent the standard error of the mean (SEM), n= 3. b In
vitro degradation of CLPX by LONM6 protease (400 nM) in the absence or presence of 1 µM PDIP38. Samples were separated by 10% Tris-Tricine SDS-
PAGE and analysed by CBB staining. *LONM impurity. c Quantitation of in vitro degradation of CLPX by LONM6 (400 nM) in the absence (open symbols,
blue crosses represent individual data points) or presence (closed symbols, red crosses represent individual data points) of untagged PDIP38. Samples
were separated by SDS-PAGE and analysed by CBB staining. Error bars represent the SEM of three independent experiments.
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However, in contrast to the idea that CLPX is degraded auto-
catalytically, the in vitro stability of CLPX was unchanged by the
presence of CLPP (Supplementary Fig. 7a). Next, in light of recent
findings63, which suggested that CLPX is a substrate of LONM,
we speculated that PDIP38 might regulate the steady-state levels
of CLPX in vivo by inhibiting its LONM-mediated turnover. To
explore this possibility, we initially monitored the in vitro stability
of CLPX in the presence of LONM, with or without the addition
of PDIP38 (Fig. 4b). Consistent with the recent findings63, CLPX
was degraded by LONM with a half-life of ~60 min (Fig. 4c, open
circles). Crucially, the LONM-mediated turnover of CLPX was
inhibited by the addition of PDIP38 (Fig. 4b, lanes 8–13; Fig. 4c,
filled circles). Moreover, the PDIP38-mediated inhibition of
LONM was specific to CLPX turnover, as the addition of PDIP38
had no effect on the LONM-mediated turnover of casein (Sup-
plementary Fig. 7b). Finally, we compared the steady-state levels
of CLPX in cells lacking PDIP38, either in the presence of normal
or depleted levels of LONM (Supplementary Fig. 6c). Consistent
with our in vitro findings, depletion of LONM (by siRNA
knockdown) partially restored the steady-state levels of CLPX in
cells lacking PDIP38 (Supplementary Fig. 6c, compare lanes 2 and
3). Therefore, the PDIP38-mediated inhibition of CLPX turnover
is in part due to PDIP38 shielding an exposed degron within
CLPX that is normally recognised by LONM. Given the location
of PDIP38 docking, this suggests that the CLPX degron is most
likely located within the ZBD of CLPX. Collectively, these data
suggest that the cellular levels and activity of mitochondrial CLPX
(P) are not only regulated by the activity of LONM, but also by
the levels of mitochondrial PDIP38.
The N-terminal domain (NTD) of PDIP38 is essential for
interaction with CLPX. Next, to better understand the molecular
basis of the interaction between CLPX and PDIP38, we examined
the domain structure of PDIP38 and determined which domain
(or domains) is required for docking to the ZBD of CLPX. To
identify domain boundaries of PDIP38, we performed limited
proteolysis (using thermolysin) of the mature protein (Supple-
mentary Fig. 8). This approach demonstrated that PDIP38 is
composed of two stable structural domains, which, based on the
transient appearance of two intermediate fragments (f1′ and f2′)
are likely to be joined by an exposed linker. To identify the
boundary of these two domains, we performed six rounds of
Edman degradation on the f1 fragment, revealing the sequence
FLANHD. Based on this analysis, we defined fragment f1 as the
C-terminal DUF525 domain and generated two GST-fusion
proteins (Fig. 5a), the NTD of PDIP38 (residues 52–153) fused to
the C terminus of glutathione S-transferase (GST) (GST-
PDIP38N) and the C-terminal domain of PDIP38 (residues
157–368) fused to the C terminus of GST (GST-PDIP38C). To
determine which domain was required for docking to CLPX, we
performed a series of pull-down assays, in which H10CLPX was
immobilised to Ni-NTA agarose beads and then incubated with a
bacterial cell lysate containing either overexpressed GST-PDIP38,
GST-PDIP38N or GST-PDIP38C (Fig. 5b, lanes 2, 4 and 6,
respectively). As a control, the different GST-PDIP38 fusion
proteins were also incubated with Ni-NTA agarose beads lacking
immobilised protein (Fig. 5b, lanes 3, 5 and 7, respectively). As
expected, and consistent with Fig. 2a, full-length GST-PDIP38
was specifically eluted from the column containing immobilised
H10CLPX (Fig. 5b, lane 2). Importantly, deletion of the NTD of
PDIP38 (GST-PDIP38C) was sufficient to prevent any specific
interaction between the two proteins (Fig. 5b, compare lanes 6
and 7). Consistent with these results, the NTD of PDIP38 alone
was sufficient for interaction with CLPX as GST-PDIP38N was
specifically recovered from Ni-NTA agarose beads containing
immobilised CLPX (Fig. 5b, lane 4) and not from beads lacking
immobilised protein (Fig. 5b, lane 5). Taken together, these data
clearly demonstrate that the NTD of PDIP38 docks to the ZBD of
CLPX. Next, in order to better understand PDIP38 function, we
crystalised mature PDIP38 (residues 52–368) and solved its
structure by X-ray crystallography to 3.4 Å resolution (see Table 1
for statistics). Consistent with our biochemical analysis, the
structure of PDIP38 is composed of two domains, an N-terminal
YccV-like domain (residues 64–186) and a C-terminal DUF525
domain (residues 231–368), which are separated by a short linker
region (Fig. 5c). The N-terminal YccV-like domain forms an
antiparallel β-sheet structure composed of six β-strands (β0–β5–
β1–β2–β3–β4), in which strands β0 to β4 are connected by loops
and β4 and β5 is connected by a short 310 helix (Fig. 5c and
Supplementary Fig. 9). Interestingly, in contrast to bacterial YccV
(HspQ) homologues, the YccV-like domain of PDIP38 contains a
large insertion between β2 and β3, which forms an extended
structural element that contacts the C-terminal DUF525 domain.
Specifically, β2/β3 extension forms an antiparallel β-sheet with β8
and the proximal sheet of the C-terminal DUF525 domain. Not
surprisingly, the β8-strand of PDIP38 is also absent from bacterial
ApaG homologues, suggesting that both of these regions have
evolved in order to stabilise the interaction of the two PDIP38
domains. In addition to the extended β2/β3-sheet, the NTD of
PDIP38 orthologues also contain an additional insertion, located
between β3 and β4 (residues 143–166). This insertion is not only
exposed in human PDIP38 (as it was susceptible to partial pro-
teolysis), but is also highly flexible as it was not visible in the
structure, presumably due to disorder. Based on the expected
location of this loop, suspended over the putative substrate-
binding pocket (see later) of the C-terminal DUF525 domain, we
speculate that the L4 loop could play a role in regulating
substrate-binding to the CTD. The linker (or intermediate)
region, which connects the N- and C-terminal domains, is formed
by a small N-terminal α-helix (α1), a two-stranded antiparallel β-
sheet (β6 and β7) and a C-terminal α-helix (α2). This domain
makes extensive contact to the NTD, wrapping around the
domain, which appears to form a hinge point for movement of
the CTD and potential delivery of its “cargo” to the associated
ATPase component, CLPX. The CTD of PDIP38 (residues
231–368) forms an immunoglobulin-like fold. However, in con-
trast to its bacterial homologues (i.e. ApaG), which form a seven-
stranded β-sandwich, PDIP38 contains an additional strand (β8),
forming an eight-stranded β-sandwich composed of two four-
stranded antiparallel β-sheets. The proximal sheet is composed of
β8–β9–β10–β13, while the distal sheet is composed of strands
β12–β11–β14–β15. Interestingly, although this domain exhibits
only weak amino acid identity (~30%) with bacterial ApaG
proteins and select eukaryotic F-box proteins with “other”
domains (i.e. Fbxo3), all of these proteins share considerable
structural homology (root-mean-squared deviation of ~1.5 Å for
superposition of Cα atoms). Notably, the DUF525 domain of
human Fbxo3 is essential for substrate recognition by the SCF-
Fbxo3 ubiquitin ligase64,65. Therefore, to gain a better under-
standing of PDIP38 function, we compared the known structure
of human Fbxo3 DUF525 domain with our structure of human
PDIP38 DUF525 domain and several other bacterial ApaG pro-
teins (Supplementary Fig. 10). From this analysis, we identified a
conserved hydrophobic groove, located between the two β-sheets
of the C-terminal domain (Fig. 5d and Supplementary Fig. 10).
Significantly, all but one of the nine hydrophobic residues are
absolutely conserved from bacteria to humans (see Supplemen-
tary Table 1 and Supplementary Fig. 11), hence we propose that
this groove plays an important role in substrate recognition.
Consistently, the Fbxo3 substrate antagonist BC-1215 is proposed
to dock into this conserved hydrophobic groove66,67. Based on its
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similarity to the substrate-binding domain of Fbxo3, we speculate
that the CTD of PDIP38 is responsible for the recognition of as
yet undefined proteins, and hence their delivery to CLPX, for
removal by the CLPXP protease. Taken together, these data
indicate that PDIP38 possesses key structural elements required
to function as an adaptor of a AAA+ protein, specifically mito-
chondrial CLPX (Fig. 5e). PDIP38 contains a distinct NTD
that docks to the accessory ZBD of CLPX (a well-established
adaptor protein binding platform in bacterial homologues) and
a distinct C-terminal domain, with likely capacity to support
protein–protein interaction, to either, directly facilitate substrate
delivery to CLPXP or indirectly regulate the CLPXP protease
function.
Discussion
We report the structural and functional characterisation of
PDIP38, a component of the PN in mammalian mitochondria.
Our biochemical analysis of PDIP38 shows that it is imported
into the mitochondrion where is interacts specifically with the
AAA+ unfoldase, CLPX (Fig. 1). PDIP38, however, is neither a
substrate of CLPXP nor does it cause dissociation of the CLPXP
complex (Fig. 2). We propose that PDIP38 is a modulator of the
CLPXP protease. This proposal is based on our biochemical and
cellular analysis of PDIP38, which demonstrate that PDIP38 not
only fine-tunes the proteolytic activity of CLPXP in vitro, but also
stabilises the cellular levels of CLPX by protecting CLPX from
LONM-mediated degradation (Fig. 4). These features are com-
monly found in several bacterial AAA+ adaptor proteins
including the bacterial N-recognin, ClpS, which modulates both
the specificity and the stability of its cognate unfoldase (ClpA)
both in vitro and in vivo30,52,68–70. Our structural and bio-
chemical studies demonstrate that PDIP38 is composed of two
domains that are joined by a hinge region. The NTD is composed
of a YccV-like fold, which is essential for interaction with CLPX.
Interestingly, similar to the E. coli adaptor protein SspB28,60,61,
PDIP38 docks to a specific region within the ZBD of CLPX
(termed the adaptor-docking loop). Mutation of this loop (in
either the ZBD or full-length CLPX) abolishes PDIP38 docking,
without affecting peptide binding by the ZBD (Fig. 3). Intrigu-
ingly, the YccV-like domain is found in several proteins that are
involved in regulated proteolysis. In bacteria, YccV (also known
as HspQ) was recently shown to be a substrate-like activator of
the AAA+ protease, Lon71. Specifically, HspQ enhances the Lon-
mediated turnover of specific substrates, including YmoA.
However, in the absence of these substrates, HspQ is rapidly
degraded by Lon71. Interestingly, under conditions of high acetyl-
CoA, HspQ becomes acetylated and its turnover by Lon is
inhibited70. This results in the accumulation of Ac-HspQ in the
cell, which binds to ClpS and inhibits the turnover of N-degron
substrates by ClpAP70. Remarkably, in Arabidopsis thaliana
another YccV-like protein, termed ClpF is also believed to
modulate the activity of ClpS72, a putative plastid-localised N-
recognin, for delivery of N-degron bearing substrates to the AAA+
protease, ClpCP73,74. Hence, it appears that YccV-like proteins not
only regulate proteolytic pathways and/or machines in bacteria
and the plastids of plants but also in human mitochondria as
Fig. 5 PDIP38 structure and proposed substrate delivery. a Schematic representation of GST-PDIP38 fusion constructs (preprotein numbering is used).
b In vitro pull-down using Ni-NTA agarose with (lanes 2, 4 and 6) or without (lanes 3, 5 and 7) purified immobilised H10CLPX, incubated with E. coli lysate
expressing GST-PDIP38 (lanes 2 and 3), GST-PDIP38N (lanes 4 and 5) or GST-PDIP38C (lanes 6 and 7). Eluted fractions are shown with samples analysed
by Coomassie Brilliant Blue (CBB) staining or immunoblotting (with anti-GST) following separation by SDS-PAGE. As a control, purified H10CLPX is shown
in lane 1. Full gels and immunoblots are shown in Supplementary Fig. 17. c Ribbon representation of human PDIP38 highlighting its two domains. The
N-terminal yccV-like (NTDYccV-like) domain (orange) and the C-terminal DUF525 (CTDDUF525) domain (blue) are separated by a hinge or linker region
(red). Two unstructured loops (L3 and L4) within the NTDYccV-like domain are illustrated by dotted lines. d Ribbon representation of human PDIP38
(orange), highlighting the conserved hydrophobic residues (sidechains shown) that line the proposed substrate-binding groove of Fbxo3 (as described in
Supplementary Table 1 and Supplementary Figs. 11 and 12). The docking site for interaction with the ZBD of CLPX is also indicated. e Cartoon
representation of the interaction between mitochondrial PDIP38 and CLPX(P), illustrating the proposed recognition of a substrate via the CTD, for its
delivery to CLPX, either for disassembly (via CLPX) or degradation (via CLPXP).
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revealed by our data. Given the obvious evolutionary relationship
of these proteolytic systems, it will be fascinating to see if PDIP38
plays any role in regulating a potential N-degron pathway in
human mitochondria48.
Similar to the NTD, the C-terminal domain of PDIP38 has also
been identified in components of mammalian degradation path-
ways. In this case, the CTD is composed of an immunoglobulin
fold (DUF525), which is not only found in bacterial ApaG pro-
teins of unknown function but also occurs in a subset of Fbxo
proteins (including Fbxo3). Significantly, Fbxo3 is the substrate
recruitment component of a multidomain E3 ligase, termed the
SCF complex (specifically the SCF-Fbxo3 complex). Importantly,
Fbxo3 (and more specifically the DUF525 domain of Fbxo3) is
essential for substrate (Fbxl2) recognition by the SCF-Fbxo3
complex66,67. Moreover, the recognition and ubiquitylation of
Fbxl2 (by the SCF-Fbxo3 complex) can be completely abolished
by docking of a small-molecule inhibitor (BC-1215) into the
substrate-binding pocket of Fbxo366,67. Importantly, the substrate
pocket of Fbxo3 is conserved across all DUF525-containing
proteins, including ApaG and mitochondrial PDIP38 (Supple-
mentary Figs. 11 and 12). Hence, based on its similarity to Fbxo3,
we speculate that the DUF525 domain of PDIP38 also facilitates
the binding and delivery of a substrate to CLPXP (Fig. 5e).
However, to date, we have yet to identify a ligand of PDIP38 that
is delivered to CLPXP. Regardless of this speculative delivery
function, PDIP38 clearly stabilises the cellular levels of CLPX
(inhibiting its turnover by LONM) and modulates the substrate
specificity of CLPXP in vitro. As such, we propose that mito-
chondrial PDIP38 is a regulator of the CLPXP protease. Inter-
estingly, PDIP38 has recently been identified as a PrimPol-
interacting protein; however, the relevance of this interaction
in mitochondria is currently unclear, as the N-terminal
mitochondrial targeting sequence of PDIP38 was identified (by
chemical cross-linking experiments) as the major site of this
interaction and the mature form of PDIP38 was unable to sti-
mulate PrimPol DNA synthesis75. Therefore, many important
questions about the function of mitochondrial PDIP38 still
remain. What are the physiological substrates of mitochondrial
PDIP38? In addition, PDIP38 is one of a growing number of
mitochondrial proteins that also appears to “moonlight” in the
nucleus76. The link, however, between the proposed function of
PDIP38 within these two compartments remains a crucial ques-
tion. How is the subcellular location of PDIP38 controlled and
what is the significance of its dual localisation in cells? Similarly,
given PDIP38 and Fbxo3 share a conserved domain (DUF525),
which is essential for Fbxo3 function, this begs the question, is
there crosstalk between these two proteins, outside the mito-
chondria? It will be fascinating to investigate the expression and
targeting of PDIP38 to mitochondria (and the nucleus) in dif-
ferent cell types and/or at different developmental stages in
mammals, not only in relation to the steady-state levels of CLPX,
but also in relation to the turnover of Fbxo3 substrates. Finally,
the future identification of physiological targets of the mito-
chondrial CLPXP/PDIP38 complex are eagerly awaited. These
data will be invaluable to further develop our understanding of
this system and its contribution to mitochondrial proteostasis.
Methods
Plasmids. For in vitro transcription and translation of human PDIP38, pOTB7/
PDIP38 was obtained from the I.M.A.G.E. Consortium (ID 3349399). For the
heterologous expression of PDIP38 in E. coli, the cDNA coding for mature PDIP38
(residues 52–368) was amplified by PCR from pOTB7/PDIP38 using the appro-
priate primers (Supplementary Table 2) and cloned into either pHUE49 between
SacII and HindIII (to express untagged PDIP38), pET10N77 between NotI and
XhoI (to express PDIP38 with an N-terminal H10 tag), pET10C77 between NdeI
and NotI (to express PDIP38 as a C-terminal H10 fusion protein), pGEX-4T-1
between BamHI and XhoI (to express PDIP38 as an N-terminal GST-fusion
protein) or pDD17378 between NotI and HindIII (to express PDIP38 as a C-
terminal GFP fusion protein with an N-terminal H10 tag). To generate PDIP38N
(residues 52–153) and PDIP38C (residues 157–368) fused to GST, pGEX-4T/
PDIP38 was subjected to site-directed mutagenesis79 using primers PDIP_bam1
and PDIP_bam2 (see Supplementary Table 2). The resulting plasmid (pDT1367,
see Supplementary Table 3) contained a stop codon and an additional BamHI site
(and was used directly for the expression of GST-PDIP38N). To generate GST-
PDIP38C, pDT1367 was digested with BamHI, the cut vector ligated lacking the
PDIP38N fragment to generate pDT1362. Plasmids for bacterial expression of
human CLPX (full-length and domain mutants) and human CLPP (either His
tagged and untagged) were described previously80. For expression of CLPX4A and
ZBD4A, pET10C/hCLPX4A and pET10C/hZBD4A were generated by site-directed
mutagenesis using appropriate primers (see Supplementary Table 2). For details of
primer sequences and plasmid constructs, refer to Supplementary information. All
clones were confirmed by Sanger sequencing.
Proteins. Recombinant proteins were expressed, either in BL21-CodonPlus®
(DE3)-RIL or XL1-Blue (Agilent) E. coli cells, grown in 2xYT media (containing
appropriate antibiotic). Protein expression was induced with the addition of 0.5
mM isopropyl-β-D-thiogalactosidase at OD600 ~0.8 and cultures were grown for at
least 4 h at 20 °C. Following expression, His-tagged (H6- or H10-) recombinant
proteins were purified from E. coli lysates under native conditions by immobilised
metal affinity chromatography using Ni-NTA agarose (Qiagen) essentially as
described15 using 50 mM Tris-HCl [pH 8.0], 300 mM NaCl supplemented with an
appropriate concentration of imidazole for binding (10 or 20 mM), washing (20 or
65 mM) and elution (250 or 500 mM). Purified His6-Ub-PDIP38 and His6-Ub-
CLPP were cleaved using His6-Usp2cc49 and the untagged mature proteins
recovered via a method outlined previously49,69. GST-PDIP38 was purified by
affinity chromatography using GSH agarose (Bioserve) as outlined by the manu-
facturer. Radiolabelled PDIP38 preprotein was synthesised using TNT® SP6 Quick
Coupled Transcription-Translation System (Promega) with undigested pOTB7/
PDIP38 as template and 11 μCi of [35S]Met/CysEXPRE35S35S protein labelling mix
(specific activity of >1000 Ci/mmol) from Perkin Elmer. Protein assay (Bio-Rad)
was used to determine protein concentrations using bovine serum albumin
(Thermo Scientific) as a standard. Protein concentrations refer to the protomer,
unless otherwise stated. FITC-casein, thermolysin, Prot. K and hen egg white
lysozyme were purchased from Sigma-Aldrich, and DNase I was purchased from
Gold Biotechnology. SeeBlue® Plus2 pre-stained and Mark12TM unstained protein
standards were from Life Technologies.





a, b, c (Å) 120.1, 120.1, 48.6
α, β, γ (°) 90, 90, 120
Resolution (Å) 39.31–3.39 (3.60–3.39)
Rsym or Rmerge 0.13 (1.44)
CCa in outermost shell 73.1
<I/σI> 15.6 (2.39)




Resolution (Å) 40–3.39 (4.27–3.39)






Average B factor (Å2): all atoms 160
R.m.s. deviations
Bond lengths (Å) 0.002
Bond angles (°) 0.57
Ramachandran statistics
Residues in favoured region, no. (%) 92.8
Residues in allowed region, no. (%) 6.8
Residues in outlier region, no. (%) 0.4
PDB entry 6ZLX
aValues within parentheses are for highest-resolution shell.
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Electrophoresis and protein detection. Proteins were separated using either
glycine- or Tricine-buffered81 sodium dodecyl sulfate-polyacrylamide gel electro-
phoresis (SDS-PAGE). Protein samples in 1× SDS-PAGE sample buffer (80 mM
Tris-HCl [pH 6.8], 2% (w/v) SDS, 5% (v/v) glycerol, 100 mM dithiothreitol (DTT)
and 0.02% (w/v) bromophenol blue) were heat treated at 95 °C for 5 min before
separation. For visualisation of proteins, gels were stained with Coomassie Brilliant
Blue R250 solution (CBB) or transferred to polyvinyldiflouride (PVDF) membrane
using semi-dry method for immunoblotting. Primary antibodies: anti-PDIP38
(POLDIP2; Abcam ab109805), anti-PDIP38 (125/88; generated in rabbit using
purified recombinant PDIP38-H10 as antigen), affinity-purified anti-CLPX15, anti-
LONM15, anti-TIM23 (BD Biosciences), anti-SDHA (Invitrogen), anti-GST (GE
Healthcare), and anti-GAPDH (Life Technologies) were used at 1:1000 for Western
blotting. Peroxidase-coupled secondary antibodies: anti-rabbit, anti-mouse and
anti-goat IgG (Sigma-Aldrich) were used at 1:5000 for Western blotting. Antibody
complexes were detected using enhanced chemiluminescence detection reagents
(GE Healthcare) and digital images captured using GeneSnap (SynGene) or Image
LabTM software (Bio-Rad). FITC-casein was detected by in-gel fluorescence
(excitation 488 nm and emission 526 nm), while radiolabelled proteins were
detected by exposing dried gels to phosphor screens. Imaging was performed using
a TyphoonTM Trio variable mode imager and analysed using the ImageQuant
software (GE Healthcare).
Limited proteolysis. H10PDIP38 (0.1 mg/ml) was subjected to limited proteolysis
using thermolysin (0.01 mg/ml) at 30 °C in 50 mM Tris-HCl [pH 7.0], 150 mM
NaCl and 5 mM CaCl2. To terminate the reaction, samples were treated with 2 mM
phenylmethanesulfonyl fluoride (PMSF) and heated at 95 °C in 1× SDS-PAGE
sample buffer.
Degradation assays. The CLPXP-mediated degradation of FITC-casein was
performed essentially as described26. Briefly, 0.4 µM CLPX6P14 was preincubated
(at 30 °C for 5 min) in proteolysis buffer (50 mM Tris-HCl [pH 8.0], 100 mM KCl,
20 mM MgCl2, 1 mM DTT, 0.02% (v/v) Triton X-100, 10% (v/v) glycerol) with
FITC-casein (0.3 µM) in the absence or presence of 2.4 µM untagged PDIP38. To
initiate degradation, 5 mM ATP was added and samples were incubated at 30 °C
for the times indicated. Reactions were terminated by the addition of 1× sample
buffer and the proteins denatured at 95 °C for 5 min.
In vitro binding analysis. The in vitro binding analysis was adapted from the
method outlined in ref. 82. Escherichia coli cells containing expressed GST-PDIP38,
GST-PDIP38N, GST-PDIP38C or untagged PDIP38 were resuspended (5 ml/g wet
weight of cells) in binding buffer (20 mM HEPES-KOH [pH 7.5], 100 mMK(OAc),
10 mM Mg(OAc), 10% (v/v) glycerol, 65 mM imidazole) supplemented with 0.5%
(v/v) Triton X-100, EDTA-free protease inhibitor cocktail (Roche), 2 mM PMSF,
and DNase I (10 μg/ml), and then subjected to chemical lysis with lysozyme (0.2
mg/ml). Cell-free lysates or purified untagged PDIP38, as appropriate, were applied
to Ni-NTA agarose beads either lacking or containing immobilised H10-tagged
CLPX, CLPXZBD, CLPXE, ecClpXZBD, CLPX4A or ZBD4A and incubated with end-
over-end mixing at 4 °C for 30 min. The beads were then washed with five bed
volumes (BVs) of binding buffer supplemented with 0.5% (v/v) Triton X-100,
followed by 10 BV of wash buffer (binding buffer supplemented with 0.25% (v/v)
Triton X-100). Bound proteins were eluted with elution buffer (50 mM Tris-HCl
[pH 8.0], 300 mM NaCl, 500 mM imidazole). For binding assays containing full-
length wild-type or mutant CLPX, all buffers were supplemented with 2 mM ATP
and 10mM β-mercaptoethanol.
Cell culturing and treatment. HeLa cells (a kind gift from Prof. N. Hoogenraad
and validated by Cellbank Australia) were cultured in Dulbecco’s modified Eagle’s
medium (Life Technologies) supplemented with 10% (v/v) foetal calf serum at
37 °C under an atmosphere of 5% (v/v) CO2. Transfection of plasmid (10 µg) or
10–20 nM synthetic siRNA (Life Technologies) was performed using Lipofecta-
mine® 2000 Transfection Reagent (Life Technologies) as per the manufacturer’s
instructions and cells grown for a further 24–72 h, as indicated. For interference of
PDIP38 mRNA, three independent synthetic siRNA (Life Technologies) were used:
Silencer No. 22994 and Silencer Select Nos. s25055 (s55) and s25056 (s56). The
corresponding Silencer Negative Control and Silencer Select Negative Controls No.
1 (nc1) and No. 2 (nc2) were used. For analysis, cells were detached by trypsin
treatment (0.25% (w/v) trypsin, 1 mM EDTA; Invitrogen) and washed cell pellets
lysed using TC extraction buffer (50 mM Tris-HCl [pH 7.5], 375 mM NaCl, 1 mM
EDTA, 1% (v/v) Triton X-100) freshly supplemented with 2 mM PMSF. Soluble
lysate was collected and used for analysis.
Mitochondrial isolation and manipulation. Crude mitochondria were isolated
from HeLa cells as described15,83. In vitro import84 was performed at 37 °C with
[35S]Met/Cys-labelled preprotein and isolated mitochondria resuspended in import
buffer (20 mM HEPES-KOH [pH 7.4], 250 mM sucrose, 5 mM Mg(OAc), 80 mM
K(OAc), freshly supplemented with 10 mM Na succinate, 1 mM DTT, 2% (w/v)
fatty acid-free BSA, 5 mM ATP and 5 mM methionine. A mix of valinomycin
(2 µM) and oligomycin (10 µM) was used to dissipate the membrane potential.
Following import, mitochondria resuspended in SEM (250 mM sucrose, 1 mM
EDTA, 10 mM MOPS-KOH [pH 7.2]) were treated with ~40 µg/ml Prot. K for 15
min at 4 °C. Mitoplasts were formed in nine parts EM buffer (10 mM MOPS-KOH
[pH 7.2], 1 mM EDTA) to one part SEM buffer at 4 °C for 20 min with gentle
pipetting84. For protease treatment, mitochondria in SEM buffer, mitoplasts in EM
buffer and lysed mitochondria in SEM buffer with 0.5% (v/v) Triton X-100 were
incubated on ice with 50 μg/ml Prot. K for the times indicated. Prot. K was
inhibited by the addition of 2 mM PMSF and proteins were immediately pre-
cipitated with trichloroacetic acid for analysis.
Immunoprecipitation. Mitochondrial lysate in IP buffer (50 mM Tris-HCl [pH
7.5], 100 mM KCl, 10 mM Mg(OAc), 5% (v/v) glycerol) containing 0.5% (v/v)
Triton X-100, 10 mM ATP and 2mM PMSF was mixed with PAS covalently
attached to antibodies (anti-PDIP38 or anti-CLPX) by end-over-end rotation for 1
h at 4 °C. Beads were washed with 3 BV of IP buffer containing 0.25% (v/v) Triton
X-100, 10 mM ATP and 2mM PMSF and antibody bound protein eluted using 1
BV of 50 mM glycine [pH 2.5].
Peptide library. To examine the peptide binding specificity of human CLPX ZBD,
peptide libraries (JPT Peptide Technologies) composed of 13-mer peptides (over-
lapping by 10 residues) derived from mtSSB and EFTu were immobilised to a
cellulose membrane (see Supplementary Figs. 4 and 5, respectively, for peptide
sequences) and panned with either ZBD or ZBD4A, essentially as described pre-
viously33 with minor modifications. Each peptide library was incubated either with
ZBD or ZBD4A (2.5 μM) in MP2 buffer (15.7 mM Tris-HCl [pH 7.6], 100 mM KCl,
20 mM MgCl2, 5% (w/v) sucrose, 0.05% (v/v) Tween-20) for 30 min with gentle
shaking at room temperature. Following transfer to a PVDF membrane as
described in ref. 33, the bound proteins were detected by immunodecoration using
anti-human CLPX antisera (1:1000 dilution in 3% (w/v) skim milk powder/TBS+
0.05% (v/v) Tween-20 (TBS-T)), washed in 1× TBS-T before being incubated with
anti-rabbit IgG conjugated with horse (Sigma-Aldrich; 1:5000 dilution in 3% (w/v)
skim milk powder/TBS-T) and visualised using GelDoc™ XR+ (Bio‐Rad) imaging
system and images captured using QuantityOne (Bio‐Rad). Figures were generated
by overlaying 4–5 membrane images with adjusted transparency (100%, 50%, 33%,
25%, 20%) to ensure that all images had equal contribution to the overall result.
Fluorescent detected analytical ultracentrifugation. The interaction of PDIP38
(GFP-PDIP38) with CLPXTRAP and CLPXTRAPP was analysed via FD-AUC,
essentially as described by ref. 85. GFP-PDIP38 (50 nM), CLPXTRAP (500 nM) and
CLPP (2.8 µM) were prepared in 350 µl of XP-AUC buffer (50 mM Tris-HCl [pH
8.0], 100 mM KCl, 20 mM MgCl2, 0.02% (v/v) Triton X-100, 10% (v/v) glycerol, 1
mM DTT, 5 mM ATP) and loaded into chilled aluminium cells fitted with a two-
channel charcoal/epon centrepiece and sapphire windows (adjusted to 125 Psi)
containing 50 µl of FC-43 heavy oil (3M, ID no. 98-0204-0101-8). Loading holes
were sealed with thin plastic covers and screws, and cells were loaded into a
prechilled An-50 Ti rotor (Beckman Coulter). The density and viscosity (poise) of
the buffer was experimentally determined to be 1.0394 and 1.902 × 10−2, respec-
tively, in a DMA 4100 densitometer and Anton Paar AMVn automated micro
viscometer (MEP instruments) fitted with a 1.6 mm capillary tube and 1.5 mm ball.
Sedimentation velocity experiments were performed at 10 °C using an XL-A ana-
lytical ultracentrifuge (Beckman Coulter) retrofitted with an Aviv Biomedical
fluorescence detector. Samples were centrifuged at 725 × g to optimise gain settings,
and radial scans were collected at 72,500 × g continuously between 5.8 and 7.3 cm
using 2 × 10−4 cm increments, with fluorescence counts being measured at each
radial position (five averages). Data were fitted to a continuous c(s) and c(m) model
using SEDFIT (http://www.analyticalultracentrifugation.com).
Crystallisation, X-ray diffraction and structure determination. To investigate
the structure of PDIP38, crystal screening was performed and crystals were
obtained using 20% (w/v) PEG 8000, 100 mM HEPES, pH 7.5. Crystals were frozen
using the crystallisation condition containing 15% (w/v) glycerol. Derivatives were
prepared after the transfer of a native crystal into a drop solution containing the
crystallisation buffer and a final concentration of Pt salts (1 mM Pt solution from
the “Pt screens” purchased from Hampton Research). Crystals were incubated for
1 h in these drops, transferred into cryo solution (see above), flash frozen in liquid
nitrogen and data collected at 100 K at the Swiss Light Source (Villigen, Switzer-
land; beamline PXII). Data were recorded on a PILATUS 6M detector (Dectris,
Baden-Daettwil, Switzerland) and data reduction was performed using the program
package XDS86,87. The structure of PDIP38 was solved to 3.4 Å by single anom-
alous dispersion techniques using one Pt derivative for phasing. The model was
refined using PHENIX88. Most of the structure was unambiguously assigned in the
electron density map, except for residues 52–62 at the N terminus and the loop
regions (L3 between residues 108–126 and L4 between residues 144–167), due to
poor density. Table 1 provides the statistics for the X-ray data collection and final
refined model. Structural figures were generated using ChimeraX_Daily.
Statistics and reproducibility. For degradation assays, the reported means values
and standard error of the mean was calculated from three independent
experiments.
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Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
Data supporting the findings of this manuscript are available from the corresponding
author upon reasonable request. A reporting summary for this article is available as
a Supplementary Information file. Atomic coordinates for the PDIP38 structure have
been deposited in wwPDB under accession code PDB 6ZLX.
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